GSE122072
Shortening the half-life of Cas9 maintains its gene editing ability and reduces neuronal toxicity
Virus-mediated expression of CRISPR/Cas9 has been actively used for genome editing in animal models of genetic disorders, including neurological diseases, but the consequences of overexpressing bacterial Cas9 in the mammalian brain remain unknown. Through RNA-seq analysis, we found that virus-mediated expression of Cas9 caused systematic changes in genes involved in neuronal functions. We also generated a short-lived version of Cas9, which maintains its genome editing capacity, but significantly alleviates neurotoxicity caused by overexpressed Cas9. Thus, modification of Cas9 by shortening its half-life would help develop CRISPR/Cas9-based therapeutic approaches for treating genetic neurological disorders. Overall design: Wild type mice were injected with adeno-associated virus into the striatum. Three weeks after viral injection, the striatal tissues were collected, and gene expression profiles were analyzed by RNA-seq.